Ipsen has received the top-line results of the Phase IIb trial1 of mesdopetam2 in people with Parkinson’s disease levodopa-induced dyskinesias from IRLAB, which has been responsible for the development of mesdopetam to date. Although the trial did not meet its primary efficacy endpoint of improving ON-time without troublesome dyskinesia, there are some findings that require further analysis and consideration. Once Ipsen has completed the process of fully evaluating all the data, the Company will communicate further regarding the future of the partnership with IRLAB. Ipsen would like to thank IRLAB, the patients and clinical investigators involved in this trial for their collaboration.
To view the press release on IRLAB’s website please click here.